Subject(s)

Antirheumatic Agents/therapeutic use , Antiviral Agents/therapeutic use , Coronavirus Infections/physiopathology , Glucocorticoids/therapeutic use , Immunologic Factors/therapeutic use , Pneumonia, Viral/physiopathology , Rheumatic Diseases/drug therapy , Adult , Aged , Arthritis, Psoriatic/complications , Arthritis, Psoriatic/drug therapy , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/drug therapy , Azithromycin/therapeutic use , Betacoronavirus , COVID-19 , Cohort Studies , Coronavirus Infections/complications , Coronavirus Infections/drug therapy , Coronavirus Infections/mortality , Coronavirus Infections/therapy , Drug Combinations , Female , Humans , Hydroxychloroquine/therapeutic use , Immunoglobulins, Intravenous/therapeutic use , Lopinavir/therapeutic use , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/drug therapy , Male , Middle Aged , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/mortality , Pneumonia, Viral/therapy , Retrospective Studies , Rheumatic Diseases/complications , Ritonavir/therapeutic use , SARS-CoV-2 , Severity of Illness Index , Spondylarthropathies/complications , Spondylarthropathies/drug therapy , COVID-19 Drug Treatment